Vaccines

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

The first-ever Wegovy pill is here. Digital health firm eMed is partnering with Novo Nordisk to offer it, promising a new era of guided, responsible care.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

New AMA codes for PolarityBio's SkinTE signal a strategic step toward commercialization, aiming to ease clinical adoption for chronic wound care.

Weight Watchers now offers the new Wegovy pill, a needle-free option, betting its future on combining powerful GLP-1 drugs with its classic support.

LENZ Therapeutics partners with Lunatus to launch its breakthrough VIZZ™ presbyopia eye drops in the Middle East, targeting a vast, unmet medical need.

With promising 3-year vision data and a manufacturing breakthrough, Lineage is pioneering 'off-the-shelf' cell therapies for blindness, diabetes, and more.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

Formerly Cybin, Helus Pharma's Nasdaq launch marks a pivotal shift towards commercializing its breakthrough depression and anxiety drug pipeline.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

Amid a crucial patent appeal and a competitive market, Scilex Holding hires renowned trial lawyer Marc Kasowitz, signaling an aggressive new legal strategy.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.